This trial is testing a new drug combo to treat pancreatic cancer in patients who have advanced disease.
- Pancreatic Adenocarcinoma
- Metastatic Cancer
2 Primary · 7 Secondary · Reporting Duration: Changes from baseline to every 8 week or every 4 weeks if there is a suspicion of Progressive Disease (PD) not radiologically confirmed during treatment and until disease progression up to 3 years.
2 Treatment Groups
1 of 2
Arm 2 -VCN-01 + SoC
1 of 2
96 Total Participants · 2 Treatment Groups
Primary Treatment: Arm 2 -VCN-01 + SoC · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 18+ · All Participants · 8 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Has the combination of Arm 2 -VCN-01 and Standard of Care been accepted by the U.S. Food & Drug Administration?
"Our team have given Arm 2 -VCN-01 + SoC a score of two due to the preclinical evidence confirming its safety, but no efficacy data being available yet as this is only in Phase 2." - Anonymous Online Contributor
Are there any current opportunities to participate in this clinical trial?
"The information on clinicaltrials.gov indicates that patient recruitment for this trial has ceased. Initially posted on October 10th 2023, the last update to the study was made on March 1st of the same year; however, there are currently 777 other studies seeking participants." - Anonymous Online Contributor